Clinical biology and potential use of thrombopoietin

Canadian Journal of Gastroenterology

Volumn 14, Issue SUPPL. D, 2000, Pages

  Basser, Russell ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Clinical review; Megakaryocyte growth and development factor; Thrombopoietin

Indexed keywords

ANTINEOPLASTIC AGENT; THROMBOPOIETIN;

DRUG EFFECT; HUMAN; REVIEW; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; BLOOD PLATELETS; HUMANS; PLATELET AGGREGATION; PLATELET COUNT; THROMBOCYTOPENIA; THROMBOPOIETIN;

EID: 0034328579     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2000/681394     Document Type: Article

References (54)

1. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony- stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164-70.
2. Geller RB, Vogelsang OB, Wingard JR, et al. Successful marrow transplantation for acute myelocytic leukemia following therapy for Hodgkin's disease. J Clin Oncol 1988;6:1558-61.
3. Hammond WP, Price TH, Souza LM, Dale DC. Treatment of cyclic neutropenia with granulocyte colony-stimulating factor. N Engl J Med 1989;320:1306-11.
4. Jakubowski AA, Souza L, Kelly F, et al. Effects of human granulocyte colony-stimulating factor in a patient with idiopathic neutropenia. N Engl J Med 1989;320:38-42.
5. Muroi K, Ito M, Sasaki R, Suda T, Sakamoto S, Miura Y. Treatment of drug-induced agranulocytosis with granulocyte colony-stimulating factor. Lancet 1989;ii:55. (Lett)
6. Metcalf D. Hematopoietic regulators: Redundancy or subtlety? Blood 1993;82:3515-23.
7. Tewari A, Buhles WC, Starnes HF. Preliminary report: Effects of interleukin-1 on platelet counts. Lancet 1990;336:712-4.
8. Asano S, Okano A, Ozawa K, et al. In vivo effects of recombinant human interleukin-6 in primates: Stimulated production of platelets. Blood 1990;75:1602-5.
9. Du XX, Williams DA. Interleukin-11: A multifunctional growth factor derived from the hematopoietic microenvironment. Blood 1994;83:2023-30.
10. Metcalf D, Hilcon D, Nicola NA. Leukemia inhibitory factor can potentiate murine megakaryocyte production in vitro. Blood 1991;77:2150-3.
11. Kelemen E, Csehati I, Tanos B. Demonstration and some properties of human thrombopoietin in thrombcythemic sera. Acta Haematol 1958;20:350-5.
12. McDonald TP. Thrombopoietin: Its biology, purification, and characterization. Exp Hematol 1988;16:201-5.
13. Wendung F, Varlet P, Charon M, Tambourin P. MPLV: A retrovirus complex inducing an acute myeloproliferative leukemic disorder in adult mice. Virology 1986;149:242-6.
14. Souyri M, Vigon I, Penciolelli JF, Heard JM, Tambourin P, Wendling F. A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors. Cell 1990;63:1137-47.
15. Methia N, Louache F, Vainchenker W, Wendling F. Oligodeoxynucleotides antisense to the protooncogene c-mpl specifically inhibit in vitro megakaryocytopoicsis. Blood 1993;82:1395-401.
16. Bartley TD, Bogenberger J, Hunt P, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 1994;77:1117-24.
17. de Sauvage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryopoiesis and thrombopoicsis by the c-Mpl ligand. Nature 1994;369:533-8.
18. Lok S, Kaushansky K, Holly RD, et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994;369:565-8.
19. Kato T, Ogami K, Shimada Y, et al. Purification and characterization of thrombopoietin. J Biochem (Tokyo) 1995;118:229-36.
20. Kuter DJ, Beeler DL, Rosenberg RD. The purification of megapoietin: A physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci USA 1994;91:11104-8.
21. Wendling F, Maraskovsky E, Debili N, et al. cMpl ligand is a humoral regulator of megakaryopoiesis. Nature 1994;369:571-4.
22. Kaushansky K. Thrombopoietin: The primary regulator of platelet production. Blood 1995;86:419-31.
23. Kaushansky K. Thrombopoietin. N Engl J Med 1998;339:746-54.
24. Klein B, Zhang X-G, Lu ZY, Bataille R. Interleukin-6 in human multiple myeloma. Blood 1995;85:863-72.
25. Gurney AL, Kuang WJ, Xie MH, Malloy BE, Eaton DL, de Sauvage FJ. Genomic structure, chromosomal localization, and conserved alternative splice forms of thrombopoietin. Blood 1995;85:981-8.
26. Nichol JL, Hokom MM, Homkohl A, et al. Megakaryocyte growth and development factor. Analyses of in vitro effects on human megakaryopoiesis and endogenous serum levels during chemotherapy-induced thrombocytopenia. J Clin Invest 1995;95:2973-8.
27. Hunt P, Li YS, Nichol JL, et al. Purification and biologic characterization of plasma-derived megakaryocyte growth and development factor. Blood 1995;86:540-7.
28. Debili N, Wendling F, Katz A, et al. The Mpl-ligand or thrombopoietin or megakaryocyte growth and differentiative factor has both direct proliferative and differentiative activities on human megakaryocyte progenitors. Blood 1995;86:2516-25.
29. Ulich TR, Del Castillo J, Yin S, et al. Megakaryocyte growth and development factor ameliorates carboplatin-induced thrombocytopenia in mice. Blood 1995;86:971-6.
30. Harker LA, Hunt P, Marzec UM, et al. Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates. Blood 1996;87:1833-44.
31. Hokom MM, Lacey D, Kinstler OB, et al. Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice. Blood 1995;86:4486-92.
32. Kaushansky K, Lok S, Holly RD, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 1994;369:568-71.
33. Zeigler FC, De Sauvage F, Widmer HR, et al. In vitro megakaryocytopoietic and thrombopoietic activity of c-mpl ligand (TPO) on purified murine hematopoietic stem cells. Blood 1994;84:4045-52.
34. Broudy VC, Lin NL, Kaushansky K. Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood 1995;85:1719-26.
35. Banu N, Wang J, Deng B, Groopman JE, Avraham H. Modulation of megakaryocytopoiesis by thrombopoietin: The c-Mpl ligand. Blood 1995;86:1331-8.
36. Choi ES, Nichol JL, Hokom MM, HomKohl AC, Hunt P. Platelets generated in vitro from proplatelet-displaying human megakaryocytes are functional. Blood 1995;85:402-13.
37. Angchaisuksiri P, Carbon PL, Dessypris EN. Effects of recombinant human thrombopoietin on megakaryocyre colony formation and megakaryocyte ploidy by human CD34+ cells in a serum-free system. Br J Haematol 1996;93:13-7.
38. Ourney AL, Carver-Moore K, de Sauvage FJ, Moore MW. Thrombocytopenia in c-mpl-deficient mice. Science 1994;265:1445-7.
39. Alexander WS, Roberts AW, Nicola NA, Li R, Metcalf D. Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl. Blood 1996;87:2162-70.
40. de Sauvage FJ, Carver-Moore K, Luoh S-M, et al. Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J Exp Med 1996;183:651-6.
41. McCarty JM, Sprugel KH, Fox NE, Sabath DE, Kaushansky K. Murine thrombopoietin mRNA levels are modulated by platelet count. Blood 1995;86:3668-75.
42. Kuter DJ, Rosenberg RD. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood 1995;85:2720-30.
43. Meng YG, Martin TG, Peterson ML, Shuman MA, Cohen RL, Wong WL. Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation. Br J Haematol 1996;95:535-41.
44. Emmons RV, Reid DM, Cohen RL, et al. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 1996;87:4068-71.
45. Stoffel R, Wiestner A, Skoda RC. Thrombopoietin in thrombocytopenic mice: Evidence against regulation at the mRNA level and for a direct regulatory role of platelets. Blood 1996;87:567-73.
46. Eaton DL, de Sauvage FJ. Thrombopoietin: the primary regulator of megakaryocytopoiesis and thrombopoiesis. Exp Hematol 1997;25:1-7.
47. Nagata Y, Shozaki Y, Nagahisa H, Nagasawa T, Abe T, Todokoro K. Serum thrombopoietin level is not regulated by transcription but by the total counts of both megakaryocytes and platelets during thrombocytopenia and thrombocytosis. Thromb Haemost 1997;77:808-14.
48. Fielder PJ, Gurney AL, Stefanich E, et al. Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood 1996;87:2154-61.
49. Broudy VC, Lin NL, Sabath DF, Papayannopoulou T, Kaushansky K. Human platelets display high-affinity receptors for thrombopoietin. Blood 1997;89:1896-904.
50. Fielder PJ, Hass P, Nagel M, et al. Human platelets as a model for the binding and degradation of thrombopoietin. Blood 1997;89:2782-8.
51. Basser RL, Rasko JEJ, Clarke K, et al. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet 1996;348:1279-81.
52. Vadhan-Raj S, Murray LJ, Bueso-Ramos C, et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med 1997;126:673-81.
53. Basser RL, Rasko JE, Clarke K, et al. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood 1997;89:3118-28.
54. Fanucchi M, Glaspy J, Crawford J, et al. Effects of polyethylene glycolconjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 1997;336:404-9.